Ex vivo treatment of malignant pleural effusions with the bispecific antibody MT110 targeting EPCAM and CD3

被引：0
|
作者：
Witthauer, J. [1 ,2 ]
Schlereth, B. [2 ]
Brischwein, K. [2 ]
Jauch, K. -W. [1 ]
Mayer, B. [1 ]
机构：
[1] Univ Munich, LMU, Dept Surg, Munich, Germany
[2] Micromet AG, Munich, Germany
来源：
ONKOLOGIE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [21] Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
    Witthauer, Juliane
    Schlereth, Bernd
    Brischwein, Klaus
    Winter, Hauke
    Funke, Ilona
    Jauch, Karl-Walter
    Baeuerle, Patrick
    Mayer, Barbara
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) : 471 - 481
  • [22] Opsonization with a trifunctional bispecific (αCD3 x αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes
    Schmitt, M
    Schmitt, A
    Reinhardt, P
    Thess, B
    Manfras, B
    Lindhofer, H
    Riechelmann, H
    Wiesneth, M
    Gronau, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (04) : 841 - 848
  • [23] TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells
    Guo, Qingming
    Zhao, Peng
    Zhang, Zhen
    Zhang, Jinyu
    Zhang, Zheng
    Hua, Yanan
    Han, Bin
    Li, Ning
    Zhao, Xiaowen
    Hou, Lin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2571 - 2587
  • [24] TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells
    Qingming Guo
    Peng Zhao
    Zhen Zhang
    Jinyu Zhang
    Zheng Zhang
    Yanan Hua
    Bin Han
    Ning Li
    Xiaowen Zhao
    Lin Hou
    Cancer Immunology, Immunotherapy, 2020, 69 : 2571 - 2587
  • [25] Impact of various immune escape mechanisms on redirected lysis by T cells engaged via EpCAM/CD3 bispecific BiTE® antibody AMG 110.
    Deisting, Wibke
    Raum, Tobias
    Kufer, Peter
    Baeuerle, Patrick A.
    Muenz, Markus
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Biting Leukemia: CD33/CD3 Bispecific Antibody Constructs for the Treatment of AML
    Subklewe, Marion
    ANNALS OF HEMATOLOGY, 2017, 96 : S46 - S46
  • [27] Construction, expression and identification of bispecific antibody for targeting CD3 and B7-H3.
    Zhang, K.
    Gui, F.
    Wang, J.
    Pan, Y.
    Yang, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1743 - 1743
  • [28] Novel conditionally active bispecific EpCAM x CD3 T cell engagers targeting solid tumors.
    Cugnetti, Ana Paula G.
    Liu, Haizhen
    Wang, Jing
    Xing, Charles
    Wheeler, Christina
    Lucas, Matthew
    Chang, Cathy
    Frey, Gerhard
    Boyle, William
    Short, Jay
    CANCER RESEARCH, 2021, 81 (13)
  • [29] An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression
    Pengfei Zhang
    Bizhi Shi
    Huiping Gao
    Hua Jiang
    Juan Kong
    Jin Yan
    Xiaorong Pan
    Kesang Li
    Pengwei Zhang
    Ming Yao
    Shengli Yang
    Jianren Gu
    Hongyang Wang
    Zonghai Li
    Cancer Immunology, Immunotherapy, 2014, 63 : 121 - 132
  • [30] An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression
    Zhang, Pengfei
    Shi, Bizhi
    Gao, Huiping
    Jiang, Hua
    Kong, Juan
    Yan, Jin
    Pan, Xiaorong
    Li, Kesang
    Zhang, Pengwei
    Yao, Ming
    Yang, Shengli
    Gu, Jianren
    Wang, Hongyang
    Li, Zonghai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (02) : 121 - 132
12345